ARS Pharmaceuticals to Remove CVS Prior Authorizations by July 1 Following 3x Neffy Volume Surge
ARS Pharmaceuticals expects to secure CVS Caremark coverage and remove prior authorizations by July 1, aligned with marketing initiatives for a back-to-school surge. The company tripled neffy prescription volumes year-over-year and more than doubled revenue, with 28,000 physicians prescribing and expansion into lower decile accounts underway.
1. Approaching CVS Caremark Coverage and Authorization Removal
The company is nearing approval with CVS Caremark, which represents a significant portion of covered lives, and expects to remove prior authorization requirements by July 1. This timing aligns with marketing and field force efforts to support a back-to-school prescription surge.
2. Neffy Prescription Volume and Revenue Growth
Year-over-year neffy prescription volumes tripled, driving a more than twofold increase in revenue. Strong demand reflects the effectiveness of current sales strategies and growing market acceptance of the product.
3. Expansion of Prescriber Base
More than 28,000 physicians have prescribed neffy, with notable adoption across both high and lower decile accounts. Ongoing initiatives aim to broaden prescribing into lower decile accounts to deepen market penetration.
4. Automated Claim Conversion to Boost Script Volumes
An automated process at about 90% of pharmacies converts denied claims into a $199 cash transaction, reducing abandonment rates and negative provider feedback. This streamlined workflow is expected to support sustained growth in script volumes.